Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: A pooled post hoc analysis

Metabolism: Clinical and Experimental

Volumn 52, Issue 12, 2003, Pages 1638-1642

  Maggs, D ^a   Shen, L ^a   Strobel, S ^a   Brown, D ^a   Kolterman, O ^a   Weyer, Christian ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LONG ACTING DRUG; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAMLINTIDE; SHORT ACTING DRUG; SULFONYLUREA; AMYLOID; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOTOXICITY; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; ETHNIC GROUP; ETHNOLOGY; FEMALE; HISPANIC; HUMAN; HYPOGLYCEMIA; INCIDENCE; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEGRO; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN; WEIGHT REDUCTION; AFRICAN AMERICAN; BLOOD; CROSSOVER PROCEDURE; METABOLISM; MIDDLE AGED; PATHOLOGY;

AFRICAN AMERICANS; AGED; AMYLOID; BODY WEIGHT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 0346368339     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.06.003     Document Type: Article

References (31)

1. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998
2. UK Prospective Diabetes Study Group: Effect of intensive blood glucose control on metformin with complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
3. UK Prospective Diabetes Study Group: Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 44:1249-1258, 1995
4. Turner RC, Cull CA, Frighi V, et al.: Glycemic control with diet, sulphonylureas, metformin, or insulin in patients with type 2 diabetes mellitus (UKPDS 49). JAMA 281:2005-2012, 1999
5. Purnell J, Weyer C: Weight effect of current and experimental drugs for diabetes mellitus: From promotion to alleviation of obesity. Treat Endocrinol 2:33-47, 2003
6. Riddle MC: Should obese type 2 diabetic patients be treated with insulin, in Gill GV, Pickup JC, Williams G, (eds): Difficult Diabetes. Oxford, UK, Blackwell Science, 2001, pp 94-112
7. Henry RR, Gumbiner B, Ditzler T, et al.: Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 16:21-31, 1993
8. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
9. Del Prato S: Post-prandial hyperglycaemia - The necessity for better control. Int J Clin Pract Suppl 112:3-8, 2000
10. Lebovitz HE: Postprandial hyperglycaemic state: Importance and consequences. Diabetes Res Clin Pract 40:S27-S28, 1998
11. Eberhardt MS, Lackland DT, Wheeler FC, et al.: Is race related to glycemic control? An assessment of glycosylated hemoglobin in two South Carolina communities. J Clin Epidemiol 47:1181-1189, 1994
12. Weatherspoon LJ, Kumanyika SK, Ludlow R, et al.: Glycemic control in a sample of black and white clinic patients with NIDDM. Diabetes Care 17:1148-1153, 1994
13. Wisdom K, Gryzek JP, Havstad SL, et al.: Comparison of laboratory test frequency and test results between African-Americans and Caucasians with diabetes: Opportunity for improvement. Diabetes Care 20:971-977, 1997
14. Harris MI, Eastman RC, Cowie CC, et al.: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22:403-408, 1999
15. Agrawal L, Emanuele NV, Abraira C, et al.: Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in type 2 diabetes mellitus (VA CSDM). Diabetes Care 21:510-515, 1998
16. Weyer C, Maggs DG, Young AA, et al.: Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Des 7:1353-1373, 2001
17. Edelman SV, Weyer C: Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: Potential benefit of replacing amylin, a second b-cell hormone. Diabetes Technol Ther 4:175-189, 2002
18. Buse JB, Weyer C, Maggs DG: Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clin Diabetes 20:137-144, 2002
19. Koda JE, Fineman M, Rink TJ, et al.: Amylin concentrations and glucose control. Lancet 339:1179-1180, 1992
20. Thompson RG, Gottlieb A, Organ K, et al.: Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin and C-peptide concentrations in patients with type 2 diabetes. Diabet Med 14:547-555, 1997
21. Maggs D, Weyer C, Crean J, et al.: Mealtime amylin replacement with pramlintide markedly improves postprandial glucose excursions when added to insulin lispro in patients with type 2 diabetes: A dose-timing study. Diabetologia 45:A264, 2002 (suppl 2, abstr)
22. Fineman M, Weyer C, Maggs DG, et al.: The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 9:504-508, 2002
23. Lee JS, Vella A, Camilleri M, et al.: Vagal inhibition in the retardation of gastric emptying of solids by the amylin analog, pramlintide, in diabetes mellitus. Gastroenterology 118:A624, 2000
24. Hollander PA, Levy P, Fineman M, et al.: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes mellitus: A one year randomized controlled trial. Diabetes Care 26:784-790, 2003
25. Ratner RE, Want LL, Fineman MS, et al.: Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther 4:51-61, 2002
26. World Health Organization: Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation. WHO Tech Ref Series No. 894, Geneva, 2000
27. Raymond NR, E'eramo-melkus G: Non-insulin-dependent diabetes and obesity in the black and Hispanic population: Culturally sensitive management. Diabetes Educ 19:313-317, 1993
28. Schwartz JG, McMahan CA, Green GM, et al.: Gastric emptying in Mexican Americans compared to non-Hispanic whites. Dig Dis Sci 40:624-630, 1995
29. Bhavsar S, Watkins J, Young A: Comparison of central and peripheral administration of amylin on reduction of food intake in rats. Diabetologia 40:A302, 1997
30. Rushing PA, Hagan MM, Seeley RJ, et al.: Amylin: A novel action in the brain to reduce body weight. Endocrinology 141:850-853, 2000
31. Lutz TA, Mollet A, Rushing PA, et al.: The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord 25:1005-1011, 2001